DNA re-replication

Origin licensing

All known mechanisms that prevent DNA rereplication in eukaryotic organisms inhibit origin licensing. Origin licensing is the preliminary step for normal replication initiation during late G1 and early S phase and involves the recruitment of the pre-replicative complex (pre-RC) to the replication origins. Licensing begins with the binding of the multi-subunit ATPase, the origin recognition complex (ORC), to the DNA at the replication origins. Once bound to chromatin the ORC recruits the AAA+ ATPase Cdc6 and the coiled-coil domain protein Cdt1. Cdt1 binding and the ATPase activity of ORC and Cdc6 facilitate the loading of the minichromosome maintenance (MCM) proteins 2-7 onto the chromatin. The MCM complex is the DNA helicase that opens the helix at the replication origin and unwinds the two strands as the replication forks travel along the DNA. Elevated CDK activity at the end of G1 triggers the firing of the origins and the dismantling of the pre-RCs. High CDK levels, which are maintained until the end of mitosis, inhibit or destroy pre-RC components and prevent the origin from relicensing. A new MCM complex cannot be loaded onto the origin until the pre-RC subunits are reactivated with the decline of CDK activity at the end of mitosis. Thus, CDKs serve a dual role in the regulation of eukaryotic DNA replication: elevated CDK activity initiates replication at the origins and prevents rereplication by inhibiting origin re-licensing. This ensures that no replication origin fires twice in the same cell cycle.

Two-state model for DNA replication regulation

Early experimental evidence on the regulation of DNA replication suggests that replication origins exist in one of two states during the cell cycle: a prereplicative state in G1 and a postreplicative state from the moment of initiation until passage through mitosis. Origins of replication alternate between these two distinct states during the cell cycle. A licensing factor which is required for replication initiation binds to origins in the prereplicative state. At the G1/S transition, the factor is inactivated and cannot be restored until the cell cycle has concluded. The identification and characterization of the ORC, Cdc6, Cdt1, and the MCM complex proteins as the licensing factor gives credence to this model and suggests a means by which the oscillatory nature of CDKs in the cell cycle can regulate rereplication.

Replication regulation

Budding yeast

Rereplication regulation is best understood in budding yeast. Saccharomyces cerevisiae cells prevent rereplication by directly regulating pre-RC assembly through the CDK-mediated phosphorylation of the pre-RC components Cdc6, MCM2-7, and the ORC subunits. The phosphorylation of these components is initiated at the onset of S phase and is maintained throughout the rest of the cell cycle as CDK activity remains high. Phosphorylated Cdc6 is bound by the ubiquitin-protein ligase SCF which leads to its proteolytic degradation. CDK-dependent phosphorylation of the MCM2-7 proteins results in the complex's export from the nucleus. (Cdt1 which associates with the MCM complex is similarly exported from the nucleus). Phosphorylation of the ORC subunits presumably disrupts the ORC's ability to bind other pre-RC components. Thus, multiple mechanisms ensure that the pre-RC cannot be reassembled on postreplicative origins.

Note: Since origins fire at different times throughout S phase, it is crucial that the inhibitory mechanisms that prevent new MCM2-7 recruitment do not destabilize existing pre-RCs. Pre-RCs can remain assembled on origins that haven't fired even though rereplication inhibitory mechanisms are inhibiting or destroying pre-RC components.

Other organisms

Although CDK regulation of pre-RC assembly appears to be highly evolutionarily conserved, some differences across organisms are noted. In multicellular eukaryotes pre-RC assembly is regulated by the anaphase-promoting complex (APC) in addition to CDKs. APC, an E3 enzyme, ubiquitinates the protein geminin and targets it for degradation. Geminin normally prevents origin licensing by binding to and inhibiting Cdt1. In G1, APC activity is adequate to suppress the accumulation of geminin, thereby indirectly promoting pre-RC assembly. At the end of G1, APC is inactivated and geminin can accumulate and prevent origin re-licensing.

Cdt1 is usually upregulated by E2F-mediated transcriptional activation and by binding of human acetylase to Orc1. Proteolytic degradation of Cdt1 is a conserved mechanism in various higher order eukaryotes as well. Cdt1 is degraded through the Cul4–Ddb1–Cdt2 E3 ubiquitin ligase complex so that DNA licensing control is maintained in S and G2. Cdt1 is an important regulatory protein, and evolution has led to different pathways of regulation in different organisms. Overexpression of Cdt1 or inactivation of Geminin can lead to re-replication, as undegraded Cdt1 will induce pre-RC assembly.

Pre-RC regulation in most animals is still not well understood.

Consequences of rereplication in eukaryotic cells

Rereplication and mitotic failure are generally not programmed events, but rather result spontaneously from defects in the cell cycle machinery. Rereplication appears to give rise to dsDNA breaks which triggers a DNA damage response and arrests cells in G2. The checkpoint effectively causes a permanent cell cycle arrest and eventual apoptosis.

Rereplication can be experimentally induced by simultaneously disrupting several of the mechanisms that prevent origin re-licensing. For example, deregulation of the ORC, MCM2-7 and Cdc6 mechanisms can induce rereplication in budding yeast cells.

Note: Recent evidence suggests that although overlapping, the multiple replication regulation mechanisms should not be considered as functionally redundant; although a single mechanism may repress rereplication at greater than 99% efficiency, it may not be sufficient to maintain genome stability over many generations. Instead, it is possible that the multiplicative effect of many overlapping mechanisms is what sufficiently prevents rereplication and ensures the faithful transmission of a cell's genome.

Preventing rereplication

Cells with replication stress activate replication checkpoints so that S phase is delayed and slows down the transition to G2/M phase. When replicative stress is recognized by U-2-OS cells, human osteosarcoma cell lines with wild-type retinoblastoma (RB) and p53, the ATM/ATR-regulated DNA damage network is activated. This checkpoint response activates due to overexpression of cyclin E, which has been shown to be important in regulating the licensing system. When cyclin E is overexpressed in U-2-OS cell lines, the ATM/ATR-regulated DNA damage network results in increases in Ser 15-phosphorylated p53, γ-H2AX, and Ser 966-phosphorylated cohesin SMC1. The DNA re-replication response is different from the response taken when damage is due to oxygen radical generation. Damage from oxygen radical generations leads to a response from the Myc oncogene, which phosphorylates p53 and H2AX.

The ATM/ATR DNA damage network will also respond to cases where there is an overexpression of Cdt1. Overexpression of Cdt1 leads to accumulation of ssDNA and DSBs. Ataxia telangiectasia and Rad3 related (ATR) is activated earlier when it detects ssDNA in the earlier phases of DNA re-replication. ATR phosphorylates downstream replication factors, such as RPA2 and MCM2 or through modulation of Rb or p53. Ataxia telangiectasia mutated (ATM) activates after a larger amount of DSBs is detected at later stages of DNA re-replication. While ATM plays a role in cell cycle arrest, apoptosis, and senescence, it is also suspected to play a role in mediating DSB repair, but the exact mechanisms are not understood yet.

Rereplication in cancer

Rereplication has been implicated in tumorigenesis in model organisms and humans. Replication initiation proteins are overexpressed in tissue samples from several types of human cancers and experimental overexpression of Cdt1 and Cdc6 can cause tumor development in mouse cells. Similarly, Geminin ablation in knockout mice has been reported to enhance tumor formation. Further, these studies indicate that rereplication can result in an increase in aneuploidy, chromosomal fusions, and DNA breaks. A thorough understanding of the regulatory replication mechanisms is important for the development of novel cancer treatments.

In yeast, increased activity of G1 CDK activity usually inhibits the assembly of pre-RCs and entry into S phase with less active origins, but in cancer cells, p53 and Rb/E2F pathways are deregulated and allow entry into S phase with a reduced amount of active origins. This leads to double-strand breaks in the DNA, increased recombination, and incorrect chromosomal arrangements. The mechanism by which this damage occurs is still not known. One possibility is that reduced origin activation leads to incomplete DNA replication. Significant re-replication is only observed when all CDK regulatory pathways are inhibited.

In mammalian cells, Cdt1 and Cdc6 are much more important to re-replication regulation. Overexpression of Cdt1 and Cdc6 were found in 43/75 cases of non-small cell lung carcinomas. Targeting Cdc6 or ORC in mammalian cells does not cause substantial re-replication. Overexpression of Cdt1, on the other hand, can lead to potentially lethal re-replication levels on its own. This response is seen only in cancer cells. Overexpression of E2F family members contributes to an increase in Cdt1 and Cdc6 expression. Loss of p53 regulation in cells can also be observed frequently in cell lines that overexpress Cdt1 or Cdc6.

Endoreduplication

For the special case of cell cycle-regulated DNA replication in which DNA synthesis is uncoupled from cell cycle progression, refer to endoreduplication. Endoreduplication is an important and widespread mechanism in many cell types. It does not adhere to many of the cell cycle checkpoints and damage controls in regularly dividing cells, but it does not result in uncontrolled re-replication. Endoreduplication is a controlled process and occurs to perform a specific cell function. In some cells, it has been proposed that endoreduplication is used as a way to store nucleotides for embryogenesis and germination. In other cases, endoreduplication may be used in cells that are only used for storage of nutrients. Despite its useful functioning in many cells, endoreduplication has also been observed in cancerous cells, and it is not fully understood whether endoreduplication leads to cancerous behavior or whether other mutations lead to endoreduplication. Other mechanisms may be involved in mediating these changes.